

**Non NPL Petitioned Sites***Colorado*

Cripple Creek and Victor Gold Mining—  
Cripple Creek (PB21-102213)

*Missouri*

Amoco Oil Company [a/k/a Amoco Oil  
Company—Sugar Creek (Finds)  
SS#0716]—Sugar Creek—(PB21-  
102171)

Dated: March 16, 2001.

**Georgi Jones,**

*Director, Office of Policy and External Affairs,  
Agency for Toxic Substances and Disease  
Registry.*

[FR Doc. 01-7237 Filed 3-22-01; 8:45 am]

**BILLING CODE 4163-70-P**

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES****Agency for Toxic Substances and  
Disease Registry**

[ATSDR-166]

**Availability of Draft Chemical  
Technical Summary on Malathion**

**AGENCY:** Agency for Toxic Substances  
and Disease Registry (ATSDR),  
Department of Health and Human  
Services (HHS).

**ACTION:** Notice of availability.

**SUMMARY:** The Comprehensive  
Environmental Response,  
Compensation, and Liability Act of 1980  
(CERCLA), as amended by the  
Superfund Amendments and  
Reauthorization Act of 1986 (SARA),  
Section 104 (i)(4) [42 U.S.C. 9604(i)(4)],  
directs the Administrator of ATSDR to  
provide informational materials on  
request on health issues relating to  
exposure to hazardous or toxic  
substances to the Administrator of the  
EPA, State officials, and local officials.  
A chemical technical summary provides  
information on a specific public health  
issue related to real or possible exposure  
and is a method ATSDR uses to respond  
rapidly to requests for assistance and  
public health needs. The chemical  
technical summary will aid public  
health and public safety professionals in  
evaluating symptoms and conducting  
surveillance of human exposure to toxic  
material.

This notice announces that a chemical  
technical summary on malathion is now  
available for public comment. This  
ATSDR chemical technical summary  
reviews the scientific literature  
describing the relationship between  
exposure to malathion and possible  
resultant health effects.

**DATES:** In order to be considered,  
comments on this draft chemical  
technical summary must be received  
within forty-five (45) days from the date  
of this publication. Comments received  
after the close of the public comment  
period will be considered at the  
discretion of ATSDR based upon what  
is deemed to be in the best interest of  
the general public.

**ADDRESSES:** Requests for copies of the  
draft chemical technical summary  
should be sent to: Ms. Franchetta  
Stephens, Division of Toxicology,  
Agency for Toxic Substances and  
Disease Registry, Mailstop E-29, 1600  
Clifton Road, NE, Atlanta, Georgia  
30333, telephone 1-(888) 422-8737 or  
(404) 639-6345. Written comments  
regarding the draft chemical technical  
summary should be sent to the same  
address. ATSDR reserves the right to  
provide only one copy of the draft  
chemical technical summary free of  
charge. The document may also be  
accessed at the ATSDR Home page  
News section at [www.atsdr.cdc.gov](http://www.atsdr.cdc.gov).

Written comments submitted in  
response to this notice should bear the  
docket control number ATSDR-166.  
Because all public comments regarding  
ATSDR-166 chemical technical  
summary will be available for  
inspection, no confidential business  
information or personal medical  
information should be submitted in  
response to this notice.

**FOR FURTHER INFORMATION CONTACT:**  
Division of Toxicology, Agency for  
Toxic Substances and Disease Registry,  
Mailstop E-29, 1600 Clifton Road, NE.,  
Atlanta, Georgia 30333.

**SUPPLEMENTARY INFORMATION:** Malathion  
is an organophosphate insecticide  
commonly used to control mosquitos  
and other flying insects, especially  
during outbreaks of vector-borne  
diseases, to protect public health.  
Malathion is toxic to aquatic organisms,  
but has a relatively low toxicity for birds  
and mammals. The principal  
toxicological effect of malathion is  
cholinesterase inhibition, due primarily  
to malaoxon and to phosphorus thionate  
impurities. Levels of malathion used for  
wide-area treatment to protect the  
public from mosquito-carrying diseases  
are not likely to result in harmful effects  
in individuals who are not directly  
exposed during spraying.

Dated: March 16, 2001.

**Georgi Jones,**

*Director, Office of Policy and External Affairs,  
Agency for Toxic Substances and Disease  
Registry.*

[FR Doc. 01-7236 Filed 3-22-01; 8:45 am]

**BILLING CODE 4163-70-P**

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES****Agency for Toxic Substances and  
Disease Registry**

[ATSDR-168]

**Availability of the Draft Document,  
Public Health Reviews of Hazardous  
Waste Thermal Treatment  
Technologies**

**AGENCY:** Agency for Toxic Substances  
and Disease Registry (ATSDR), HHS.

**ACTION:** Notice of availability and  
request for public comment of the draft  
document, Public Health Reviews of  
Hazardous Waste Thermal Treatment  
Technologies.

**SUMMARY:** The Agency for Toxic  
Substances and Disease Registry  
announces the availability for public  
comment of the draft document, Public  
Health Reviews of Hazardous Waste  
Thermal Treatment Technologies.

**DATES:** Comments must be received by  
April 23, 2001.

**ADDRESSES:** The document is available  
by contacting the Chief, Program  
Evaluation, Records, and Information  
Services Branch, Agency for Toxic  
Substances and Disease Registry, 1600  
Clifton Road (E-56), Atlanta, GA 30333.  
Please submit written comments  
relating to the document to the same  
location. ATSDR reserves the right to  
provide only one copy of this draft  
document free of charge. The document  
may also be accessed at the ATSDR  
Home page News section at  
[www.atsdr.cdc.gov](http://www.atsdr.cdc.gov). Generally,  
comments submitted will be available to  
the public upon request. Information  
submitted which is claimed as personal,  
medical, or otherwise confidential and  
proprietary must be clearly marked as  
such. Information so marked will not be  
disclosed except in accordance with 45  
CFR part 5.

**FOR FURTHER INFORMATION CONTACT:**  
Further information may be obtained by  
contacting Betty C. Willis, ATSDR  
(Mailstop E-56), 1600 Clifton Road, NE,  
Atlanta, Georgia 30333, telephone (404)  
639-6071 or (toll free) 1-888-42-  
ATSDR, 1-888-422-8737, or Email:  
[bwillis@cdc.gov](mailto:bwillis@cdc.gov).

**SUPPLEMENTARY INFORMATION:** The  
Agency for Toxic Substances and  
Disease Registry (ATSDR) is the lead  
Department of Health and Human  
Services agency addressing human  
health concerns and risks in  
communities near hazardous waste sites  
or other sources of environmental  
contamination. ATSDR has specific  
responsibilities for public health

activities under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or "Superfund"). These activities include: Health consultations and public health assessments at sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public.

This draft document, Public Health Reviews of Hazardous Waste Thermal Treatment Technologies, will assist in the Agency's critical mission to reduce and prevent exposures and adverse health outcomes from exposure to hazardous substances. The document provides technical guidance for Agency staff who review thermal treatment technologies to evaluate the potential public health effects associated with the use of incinerators or thermal desorbers to treat hazardous wastes. This document contains detailed technical guidance to promote consistency among Agency staff during evaluations of thermal treatment facilities. People who do not have technical experience and knowledge of thermal technologies may find it difficult to understand.

This draft, Public Health Reviews of Hazardous Waste Thermal Treatment Technologies, is available for public comment so the Agency can benefit from public review and input before finalizing the document. This **Federal Register** notice announces that this draft

document is available for public comment.

Dated: March 19, 2001.

**Georgi Jones,**  
*Director, Office of Policy and External Affairs,*  
*Agency for Toxic Substances and Disease Registry.*

[FR Doc. 01-7235 Filed 3-22-01; 8:45 am]

**BILLING CODE 4163-70-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Proposed Information Collection Activity; Comment Request

##### *Proposed Projects*

*Title:* Refugee Resettlement Program Estimates: CMA, ORR-1.

*OMB No.* 0970-0030.

*Description:* ORR reimburses, to the extent of available appropriations, certain non-Federal costs for the provision of cash and medical assistance to refugees, along with allowable expenses in the administration of the Refugee Resettlement Program. ORR needs sound State estimates of likely expenditures for refugee cash, medical, and administrative (CMA) expenditures so that it can anticipate Federal costs in upcoming quarters. If Federal costs are anticipated to exceed budget

allocations, ORR must take steps to reduce Federal expenses, such as limiting the number of months of eligibility for Refugee Cash Assistance (RCA) and Refugee Medical Assistance (RMA).

To meet the need for reliable State estimates of anticipated expenses, ORR has developed a single-page form in which States estimate the average number of recipients for each category of assistance, the average unit cost over the next 12 months and the expense for the overall administration of the program. This form, the ORR-1 (formerly Form FSA-601) must be submitted prior to the beginning of each Federal fiscal year. Without this information, ORR would be out of compliance with the intent of its legislation and otherwise unable to estimate program costs adequately.

In addition, the ORR-1 serves as the State's application for reimbursement of its CMA expenses. Submission of this form is thus required by section 412(a)(4) of the Immigration and Nationality Act which provides that "no grant or contract may be awarded under this section unless an appropriate proposal and application \* \* \* are submitted to, and approved by, the appropriate administering official."

*Respondents:* State, Local or Tribal Govt.

#### *Annual Burden Estimates*

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
ORR-1 .....	48	1	.5	24
Estimated Total Annual Burden Hours .....	.....	.....	.....	24

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, S.W., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for proper performance of the functions

of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: March 19, 2001.

**Bob Sargis,**  
*Reports Clearance Officer.*

[FR Doc. 01-7187 Filed 3-22-01; 8:45 am]

**BILLING CODE 4184-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 01N-0114]

#### **Agency Information Collection Activities; Proposed Collection; Comment Request; Patent Term Restoration, Due Diligence Petitions, Filing, Format, and Content of Petitions**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the